sodium fluoride has been researched along with Bone Fractures in 51 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The value of intermittent slow release sodium fluoride treatment in the management of osteoporosis was studied by a comprehensive metabolic and clinical assessment during a long term trial." | 9.06 | Safe and effective treatment of osteoporosis with intermittent slow release sodium fluoride: augmentation of vertebral bone mass and inhibition of fractures. ( Johnson, K; Pak, CY; Parcel, C; Peterson, R; Sakhaee, K; Zerwekh, JE, 1989) |
| "In a 5-year observational study we have compared sodium fluoride (NaF) with different treatments commonly used in the treatment of osteoporosis: calcium, estrogens, androgens, and calcitonin, referred to as non-NaF." | 7.69 | Sodium fluoride treatment is a major protector against vertebral and nonvertebral fractures when compared with other common treatments of osteoporosis: a longitudinal, observational study. ( Armadans, L; Farrerons, J; Guañabens, N; López-Navidad, A; Renau, A; Rodríguez de la Serna, A; Vaqué, J; Yoldi, B, 1997) |
| "To evaluate the need for a randomised study of treatment of spinal osteoporosis with human parathyroid peptide in the secondary prevention of crush fractures; to study the effect of human parathyroid hormone peptide 1-34 plus sex hormones on vertebral body cancellous bone; and, separately, to determine the effect of relatively low doses of sodium fluoride plus calcium on spinal bone mineral density." | 7.68 | Treatment of osteoporosis with human parathyroid peptide and observations on effect of sodium fluoride. ( Davies, UM; Hesp, R; Katz, D; McNally, E; Reeve, J, 1990) |
| "Calcium and phosphorus balances and 47Ca turnover studies were performed before and after 12-27 months of daily treatment with sodium fluoride (60 mg), calcium (30-45 mmol), phosphate (29-44 mmol), and vitamin D2 (18,000 IU) in 20 postmenopausal women with spinal crush fracture osteoporosis." | 7.67 | The effects of sodium fluoride, calcium phosphate, and vitamin D2 for one to two years on calcium and phosphorus metabolism in postmenopausal women with spinal crush fracture osteoporosis. ( Charles, P; Jensen, FT; Mosekilde, L, 1985) |
| "The value of intermittent slow release sodium fluoride treatment in the management of osteoporosis was studied by a comprehensive metabolic and clinical assessment during a long term trial." | 5.06 | Safe and effective treatment of osteoporosis with intermittent slow release sodium fluoride: augmentation of vertebral bone mass and inhibition of fractures. ( Johnson, K; Pak, CY; Parcel, C; Peterson, R; Sakhaee, K; Zerwekh, JE, 1989) |
| " Sodium fluoride has been used to treat established osteoporosis for nearly 30 years." | 4.79 | Water fluoridation and osteoporotic fracture. ( Coggon, D; Cooper, C; Hillier, S; Inskip, H, 1996) |
| "In a 5-year observational study we have compared sodium fluoride (NaF) with different treatments commonly used in the treatment of osteoporosis: calcium, estrogens, androgens, and calcitonin, referred to as non-NaF." | 3.69 | Sodium fluoride treatment is a major protector against vertebral and nonvertebral fractures when compared with other common treatments of osteoporosis: a longitudinal, observational study. ( Armadans, L; Farrerons, J; Guañabens, N; López-Navidad, A; Renau, A; Rodríguez de la Serna, A; Vaqué, J; Yoldi, B, 1997) |
| "The effect of sodium fluoride therapy on iliac trabecular bone has been studied in 15 patients with primary osteoporosis by comparing bone biopsies taken before and after two years of treatment." | 3.68 | The effect of sodium fluoride on trabecular architecture. ( Aaron, JE; de Vernejoul, MC; Kanis, JA, 1991) |
| "To evaluate the need for a randomised study of treatment of spinal osteoporosis with human parathyroid peptide in the secondary prevention of crush fractures; to study the effect of human parathyroid hormone peptide 1-34 plus sex hormones on vertebral body cancellous bone; and, separately, to determine the effect of relatively low doses of sodium fluoride plus calcium on spinal bone mineral density." | 3.68 | Treatment of osteoporosis with human parathyroid peptide and observations on effect of sodium fluoride. ( Davies, UM; Hesp, R; Katz, D; McNally, E; Reeve, J, 1990) |
| "Calcium and phosphorus balances and 47Ca turnover studies were performed before and after 12-27 months of daily treatment with sodium fluoride (60 mg), calcium (30-45 mmol), phosphate (29-44 mmol), and vitamin D2 (18,000 IU) in 20 postmenopausal women with spinal crush fracture osteoporosis." | 3.67 | The effects of sodium fluoride, calcium phosphate, and vitamin D2 for one to two years on calcium and phosphorus metabolism in postmenopausal women with spinal crush fracture osteoporosis. ( Charles, P; Jensen, FT; Mosekilde, L, 1985) |
| "Thirty-six patients with primary osteoporosis were treated for up to six years with sodium fluoride, calcium supplements, and, in 24 patients, vitamin D." | 3.66 | Treatment of primary osteoporosis with fluoride and calcium. Clinical tolerance and fracture occurrence. ( Hodgson, SF; Hoffman, DL; Johnson, KA; Kelly, PJ; Riggs, BL; Taves, D, 1980) |
| "Osteoporosis is a metabolic bone disorder that leads to a decline in bone microarchitecture, predisposing individuals to catastrophic fractures." | 3.01 | Emerging Role of ( Collins, MT; Farhadi, F; Osamor, CC; Paravastu, SS; Saboury, B; Sheppard, AJ; Wojnowski, NM, 2023) |
| "Osteoporosis is a public health scourge that is usually eminently preventable." | 2.40 | Osteoporosis: prevention, diagnosis, and management. ( Deal, CL, 1997) |
| "Risk fractures for osteoporosis are numerous." | 2.39 | Osteoporotic fractures: background and prevention strategies. ( Wark, JD, 1996) |
| "Women are the most common victims of involutional osteoporosis because of post-menopausal bone loss induced by oestrogenic deficit." | 2.38 | Osteoporosis. ( Devogelaer, JP; Nagant de Deuxchaisnes, C, 1993) |
| "Osteoporosis is a major public health problem, particularly for the postmenopausal woman." | 2.37 | Postmenopausal osteoporosis. ( Lindsay, R; Silverberg, SJ, 1987) |
| "Osteoporosis is a frequent complication in patients with inflammatory bowel disease." | 1.35 | Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model. ( Klaus, J; König, HH; Konnopka, A; Kreck, S; Leidl, R; Matschinger, H; von Tirpitz, C, 2008) |
| "Osteoporosis is a metabolic bone disease characterized by an increased risk of fractures, especially hip, wrist and vertebral fractures." | 1.30 | [Osteoporosis: its diagnosis, its consequences]. ( Hardouin, P, 1997) |
| "Four other patients had stress fractures associated with trauma." | 1.28 | Fluoride-induced fractures: relation to osteogenic effect. ( Bayley, TA; Goodwin, S; Harrison, JE; Josse, RG; Murray, TM; Pritzker, KP; Strauss, A; Sturtridge, W; Vieth, R, 1990) |
| "Osteoporosis is the most common bone disorder in the United States." | 1.27 | Osteoporosis. ( Davies, R; Saha, S, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (37.25) | 18.7374 |
| 1990's | 22 (43.14) | 18.2507 |
| 2000's | 6 (11.76) | 29.6817 |
| 2010's | 2 (3.92) | 24.3611 |
| 2020's | 2 (3.92) | 2.80 |
| Authors | Studies |
|---|---|
| Sheppard, AJ | 3 |
| Paravastu, SS | 3 |
| Wojnowski, NM | 3 |
| Osamor, CC | 3 |
| Farhadi, F | 3 |
| Collins, MT | 3 |
| Saboury, B | 3 |
| Rezaee, T | 1 |
| Bouxsein, ML | 1 |
| Karim, L | 1 |
| Drubach, LA | 1 |
| Johnston, PR | 1 |
| Newton, AW | 1 |
| Perez-Rossello, JM | 1 |
| Grant, FD | 1 |
| Kleinman, PK | 1 |
| Klaus, J | 2 |
| Reinshagen, M | 1 |
| Herdt, K | 1 |
| Schröter, C | 1 |
| Adler, G | 1 |
| von Boyen, GB | 1 |
| von Tirpitz, C | 2 |
| Simon, LS | 1 |
| Galus, K | 1 |
| Kreck, S | 1 |
| Leidl, R | 1 |
| Konnopka, A | 1 |
| Matschinger, H | 1 |
| König, HH | 1 |
| Kanis, JA | 3 |
| Reeve, J | 3 |
| Riggs, BL | 4 |
| Seeman, E | 2 |
| Hodgson, SF | 3 |
| Taves, DR | 1 |
| O'Fallon, WM | 2 |
| Leroux, JL | 1 |
| Blotman, F | 1 |
| Claustre, J | 1 |
| Simon, L | 1 |
| Meunier, PJ | 1 |
| Schmidt, CW | 1 |
| Milhaud, G | 1 |
| Christiansen, C | 1 |
| Gallagher, C | 1 |
| Chesnut, C | 1 |
| Parfitt, A | 1 |
| Hoffman, DL | 1 |
| Kelly, PJ | 1 |
| Johnson, KA | 1 |
| Taves, D | 1 |
| McCormack, AP | 1 |
| Anderson, PA | 1 |
| Tencer, AF | 1 |
| Devogelaer, JP | 1 |
| Nagant de Deuxchaisnes, C | 1 |
| Wark, JD | 1 |
| Hillier, S | 1 |
| Inskip, H | 1 |
| Coggon, D | 1 |
| Cooper, C | 1 |
| Farrerons, J | 1 |
| Rodríguez de la Serna, A | 1 |
| Guañabens, N | 1 |
| Armadans, L | 1 |
| López-Navidad, A | 1 |
| Yoldi, B | 1 |
| Renau, A | 1 |
| Vaqué, J | 1 |
| Deal, CL | 1 |
| Hardouin, P | 1 |
| Shiflett, S | 1 |
| Cooke, CE | 1 |
| Miller, P | 1 |
| Lukert, B | 1 |
| Broy, S | 1 |
| Civitelli, R | 1 |
| Fleischmann, R | 1 |
| Gagel, R | 1 |
| Khosla, S | 1 |
| Lucas, M | 1 |
| Maricic, M | 1 |
| Pacifici, R | 1 |
| Recker, R | 1 |
| Sarran, HS | 1 |
| Short, B | 1 |
| Short, MJ | 1 |
| Blank, RD | 1 |
| Bockman, RS | 1 |
| Haguenauer, D | 1 |
| Welch, V | 1 |
| Shea, B | 1 |
| Tugwell, P | 1 |
| Wells, G | 1 |
| Ringe, JD | 1 |
| Lane, NE | 1 |
| Haas, HG | 1 |
| Sambrook, P | 1 |
| Pouillès, JM | 1 |
| Trémollières, F | 1 |
| Ribot, C | 1 |
| Aaron, JE | 1 |
| de Vernejoul, MC | 1 |
| Banting, DW | 1 |
| Skolnick, A | 1 |
| Lindsay, R | 2 |
| Bayley, TA | 2 |
| Muller, C | 1 |
| Harrison, J | 1 |
| Basualdo, J | 1 |
| Sturtridge, W | 2 |
| Josse, R | 1 |
| Murray, TM | 2 |
| Pritzker, KP | 2 |
| Vieth, R | 2 |
| Goodwin, S | 2 |
| Harrison, JE | 1 |
| Josse, RG | 1 |
| Strauss, A | 1 |
| Brückle, W | 1 |
| Cueni, M | 1 |
| Davies, UM | 1 |
| Hesp, R | 1 |
| McNally, E | 1 |
| Katz, D | 1 |
| Chao, EY | 1 |
| Wahner, HW | 1 |
| Muhs, JM | 1 |
| Cedel, SL | 1 |
| Melton, LJ | 1 |
| Minne, HW | 1 |
| Leidig, G | 1 |
| Wüster, C | 1 |
| Siromachkostov, L | 1 |
| Baldauf, G | 1 |
| Bickel, R | 1 |
| Sauer, P | 1 |
| Lojen, M | 1 |
| Ziegler, R | 1 |
| Pak, CY | 1 |
| Sakhaee, K | 1 |
| Zerwekh, JE | 1 |
| Parcel, C | 1 |
| Peterson, R | 1 |
| Johnson, K | 1 |
| Melick, RA | 1 |
| Silverberg, SJ | 1 |
| Parfitt, AM | 1 |
| Charles, P | 1 |
| Mosekilde, L | 1 |
| Jensen, FT | 1 |
| Fish, HR | 1 |
| Dons, RF | 1 |
| Power, GR | 1 |
| Gay, JD | 1 |
| Courvoisier, B | 1 |
| Baud, CA | 1 |
| Véry, JM | 1 |
| Assimacopoulos, A | 1 |
| Tochon-Danguy, HJ | 1 |
| Boivin, G | 1 |
| Donath, A | 1 |
| Garcia, J | 1 |
| Gasser, A | 1 |
| Fischer, J | 1 |
| Davies, R | 1 |
| Saha, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Changes in Bone Density, Radiographic Texture Analysis and Bone Turnover During Two Years of Antiresorptive Therapy for Postmenopausal Osteoporosis[NCT00145977] | 36 participants (Actual) | Interventional | 2001-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percent Change in femoral neck BMD from Baseline to Month 24 (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | -4.21 |
| Control | 0.04 |
Percent Change in lumbar spine BMD from Baseline to Month 24 (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | 5.28 |
| Control | -1.48 |
Percent Change in peripheral heel BMD from Baseline to Month 24 (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | 1.02 |
| Control | -1.99 |
To derive a measure of variability and directionality in the first moment of the power spectrum (FMP) in the region of interest of the bone image, the power spectrum is divided into 24 angular sectors at 15 degree intervals, and FMP is calculated for each segment. We use iFMP (integrated FMP) as a measure of overall special frequency of the radiographic pattern. FMP characterizes spatial frequency in the radiographic pattern and the underlying trabecular structure. This corresponds to the coarseness or fineness of the radiographic texture pattern. A high level of FMP indicates thin and closely spaced trabecular structure. Low FMP indicates widely spaced dark areas usually corresponding to a strong, thick trabecular structure. (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | 0.09 |
| Control | 1.04 |
"Root Mean Square (RMS) is a measure of the variability in the radiographic texture pattern, the relative difference in the contrast between light and dark areas is expressed in a grayscale level. In practical terms, a bone image with a washed-out appearance due to loss of trabecular structure such as that seen in osteoporosis, will have a low value for RMS because there will be relatively little contrast between lighter and darker areas of the image. An image of a bone with strong trabecular structure will have a high RMS value because the contrast between the lighter and darker areas of the image will be greater.~To derive a measure of variability in the RMS in the region of interest of the bone image, the power spectrum is divided into 24 angular sectors at 15 degree intervals, and RMS is calculated for each segment. We use sdRMS (standard deviation of the RMS across the segments) as a measure of the direction dependence (anisotropy) of the trabeculae in the bone image." (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | 6.85 |
| Control | 1.08 |
"Root Mean Square (RMS) is a measure of the variability in the radiographic texture pattern, the relative difference in the contrast between light and dark areas is expressed in a grayscale level. In practical terms, a bone image with a washed-out appearance due to loss of trabecular structure such as that seen in osteoporosis, will have a low value for RMS because there will be relatively little contrast between lighter and darker areas of the image. An image of a bone with strong trabecular structure will have a high RMS value because the contrast between the lighter and darker areas of the image will be greater.~To derive a measure of variability in the RMS in the region of interest in the bone image, the power spectrum is divided into 24 angular sectors at 15 degree intervals, and RMS is calculated for each segment. The iRMS (integrated RMS) roughly corresponds to RMS averaged across all 24 angular sectors" (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | -3.70 |
| Control | -0.53 |
To derive a measure of variability and directionality in the first moment of the power spectrum (FMP) in the region of interest of the bone image, the power spectrum is divided into 24 angular sectors at 15 degree intervals and FMP is calculated for each segment. We use minFMP (minimum FMP) to represent the lowest value of FMP across the 24 angular sectors corresponding to the special frequency in the most washed-out direction. FMP characterizes spatial frequency in the radiographic pattern and the underlying trabecular structure. This corresponds to the coarseness or fineness of the radiographic texture pattern. A high level of FMP indicates thin and closely spaced trabecular structure. Low FMP indicates widely spaced dark areas usually corresponding to a strong, thick trabecular structure. (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | -3.61 |
| Control | -0.18 |
The Percent Change in Radiographic Texture Analysis (RTA) Minkowski Fractal Dimension (MINK) from Baseline to Month 24 is a description of the similarity of texture of the images at different magnifications. The Minkowski fractal dimension is calculated from the slope of the least -square fitted line relating log volume and log magnification. (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | -0.06 |
| Control | 0.12 |
The Percent Change in Radiographic Texture Analysis (RTA) spectral density coefficient beta (BETA) from Baseline to Month 24 is an analysis of spectral density vs. the spacial frequency on a log-log plot. BETA is the coefficient (slope) of this plot. Higher values of beta correspond to rougher (strong bone) and lower values to smoother, higher-frequency texture pattern (washed out bone). (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | 3.09 |
| Control | 6.53 |
Percent Change in total hip BMD from Baseline to Month 24 (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | -3.68 |
| Control | -0.77 |
20 reviews available for sodium fluoride and Bone Fractures
| Article | Year |
|---|---|
Emerging Role of
Topics: Fractures, Bone; Humans; Osteoporosis; Positron Emission Tomography Computed Tomography; Sodium Fluo | 2023 |
Emerging Role of
Topics: Fractures, Bone; Humans; Osteoporosis; Positron Emission Tomography Computed Tomography; Sodium Fluo | 2023 |
Emerging Role of
Topics: Fractures, Bone; Humans; Osteoporosis; Positron Emission Tomography Computed Tomography; Sodium Fluo | 2023 |
Emerging Role of
Topics: Fractures, Bone; Humans; Osteoporosis; Positron Emission Tomography Computed Tomography; Sodium Fluo | 2023 |
Osteoporosis.
Topics: Alkaline Phosphatase; Androgens; Bone Remodeling; Calcitonin; Calcium; Diagnosis, Differential; Diph | 2005 |
[Prevention and treatment of osteoporosis].
Topics: Absorptiometry, Photon; Anticholesteremic Agents; Bone Density; Bone Density Conservation Agents; Ca | 2005 |
Should we use fluoride to treat osteoporosis? A review.
Topics: Aged; Bone and Bones; Bone Diseases; Child; Female; Fractures, Bone; Humans; Minerals; Osteoporosis; | 1984 |
Osteoporosis.
Topics: Accidental Falls; Age Factors; Aged; Bone Density; Calcitonin; Calcium, Dietary; Cost of Illness; Di | 1993 |
Osteoporotic fractures: background and prevention strategies.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alcoholism; Biomarkers; Bone and Bones; Bone Densit | 1996 |
Water fluoridation and osteoporotic fracture.
Topics: Aged; Bone and Bones; Bone Density; Female; Finland; Fluoridation; Fluorides; Fractures, Bone; Hip F | 1996 |
Osteoporosis: prevention, diagnosis, and management.
Topics: Bone Density; Calcitonin; Diphosphonates; Drug Therapy, Combination; Estrogen Replacement Therapy; F | 1997 |
Osteoporosis: a focus on treatment.
Topics: Accidental Falls; Aged; Aging; Alendronate; Bone Density; Calcitonin; Contraindications; Estrogen Re | 1997 |
Management of postmenopausal osteoporosis for primary care.
Topics: Absorptiometry, Photon; Biomarkers; Bone Density; Calcitonin; Diphosphonates; Estrogen Replacement T | 1998 |
A review of clinical trials of therapies for osteoporosis using fracture as an end point.
Topics: Calcitonin; Diphosphonates; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Male; Ost | 1999 |
Fluoride for treating postmenopausal osteoporosis.
Topics: Bone Density; Female; Fluorides; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Phosphates; | 2000 |
Past and future of anabolic agents.
Topics: Animals; Calcium; Female; Fluorides; Fractures, Bone; Human Growth Hormone; Humans; Insulin-Like Gro | 2000 |
An update on glucocorticoid-induced osteoporosis.
Topics: Animals; Bone Density; Bone Remodeling; Diphosphonates; Drug Therapy, Combination; Estrogens; Fractu | 2001 |
Calcitriol and postmenopausal osteoporosis.
Topics: Anabolic Agents; Bone Density; Calcitriol; Calcium, Dietary; Estrogen Replacement Therapy; Etidronic | 1992 |
Treatment of osteoporosis with sodium fluoride or parathyroid hormone.
Topics: Bone Density; Fractures, Bone; Humans; Osteoporosis; Parathyroid Hormone; Sodium Fluoride | 1991 |
The treatment of osteoporosis.
Topics: Adult; Age Factors; Aged; Anabolic Agents; Calcitriol; Calcium; Drug Therapy, Combination; Estrogens | 1986 |
Postmenopausal osteoporosis.
Topics: Bone Resorption; Calcium; Diagnosis, Differential; Estradiol Congeners; Estrogens; Exercise Therapy; | 1987 |
Trabecular bone architecture in the pathogenesis and prevention of fracture.
Topics: Bone and Bones; Estrogens; Female; Fractures, Bone; Humans; Menopause; Osteoporosis; Sodium Fluoride | 1987 |
Primary osteoporosis.
Topics: Aged; Calcium; Estrogens; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis; Risk; So | 1985 |
7 trials available for sodium fluoride and Bone Fractures
| Article | Year |
|---|---|
Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D.
Topics: Absorptiometry, Photon; Adult; Bone Density; Bone Density Conservation Agents; Calcium Citrate; Chol | 2011 |
Treatment of osteoporotic fracture.
Topics: Bone Development; Calcium; Clinical Trials as Topic; Double-Blind Method; Estrogens; Follow-Up Studi | 1984 |
Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. Comparison with conventional therapy.
Topics: Aged; Calcium; Clinical Trials as Topic; Drug Therapy, Combination; Estrogens, Conjugated (USP); Fem | 1982 |
Past and future of anabolic agents.
Topics: Animals; Calcium; Female; Fluorides; Fractures, Bone; Human Growth Hormone; Humans; Insulin-Like Gro | 2000 |
New doubts about benefits of sodium fluoride.
Topics: Bone Density; Clinical Trials as Topic; Female; Fractures, Bone; Humans; Osteoporosis; Sodium Fluori | 1990 |
Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.
Topics: Aged; Bone Density; Calcium; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fractures, | 1990 |
Safe and effective treatment of osteoporosis with intermittent slow release sodium fluoride: augmentation of vertebral bone mass and inhibition of fractures.
Topics: Adult; Aged; Aged, 80 and over; Bone and Bones; Calcium; Delayed-Action Preparations; Dose-Response | 1989 |
25 other studies available for sodium fluoride and Bone Fractures
| Article | Year |
|---|---|
Increasing fluoride content deteriorates rat bone mechanical properties.
Topics: Animals; Bone and Bones; Bone Remodeling; Female; Fluorides; Fractures, Bone; Rats; Sodium Fluoride | 2020 |
Skeletal trauma in child abuse: detection with 18F-NaF PET.
Topics: Child Abuse; Female; Fluorodeoxyglucose F18; Fractures, Bone; Humans; Image Interpretation, Computer | 2010 |
Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model.
Topics: Adult; Aged; Bone Density; Bone Density Conservation Agents; Calcium; Cholecalciferol; Cost-Benefit | 2008 |
Treatment of osteoporotic fracture.
Topics: Female; Fractures, Bone; Humans; Osteoporosis; Parathyroid Hormone; Peptide Fragments; Sodium Fluori | 1984 |
[Fractures of the calcaneus during fluoride therapy of osteoporosis].
Topics: Aged; Calcaneus; Female; Fractures, Bone; Fractures, Closed; Humans; Middle Aged; Osteoporosis; Radi | 1983 |
[Longevity of a population exposed to fluorides for decades].
Topics: Aged; Female; Fractures, Bone; Germany, East; Humans; Longevity; Male; Osteoporosis; Population Dyna | 1984 |
Pathogenesis and treatment of postmenopausal osteoporosis.
Topics: Aged; Calcitonin; Calcitriol; Female; Fractures, Bone; Hormones; Humans; Malabsorption Syndromes; Me | 1983 |
Treatment of primary osteoporosis with fluoride and calcium. Clinical tolerance and fracture occurrence.
Topics: Adult; Aged; Anemia, Hypochromic; Calcium, Dietary; Drug Therapy, Combination; Female; Fluorides; Fr | 1980 |
Effect of controlled local release of sodium fluoride on bone formation: filling a defect in the proximal femoral cortex.
Topics: Animals; Bone and Bones; Bone Density; Bone Development; Disease Models, Animal; Femur; Fracture Hea | 1993 |
Sodium fluoride treatment is a major protector against vertebral and nonvertebral fractures when compared with other common treatments of osteoporosis: a longitudinal, observational study.
Topics: Administration, Oral; Aged; Female; Follow-Up Studies; Fractures, Bone; Humans; Longitudinal Studies | 1997 |
[Osteoporosis: its diagnosis, its consequences].
Topics: Absorptiometry, Photon; Adolescent; Adult; Aged; Bone Resorption; Calcium, Dietary; Diphosphonates; | 1997 |
[Treatment of osteoporosis (author's transl)].
Topics: Calcium; Female; Fractures, Bone; Humans; Male; Osteoporosis; Physical Therapy Modalities; Sodium Fl | 1976 |
[Comparative effects of sodium fluoride and hormonal replacement therapy on bone metabolism in osteoporotic women with high fracture risk. Results of monitoring for 2 years].
Topics: Age Factors; Aged; Bone and Bones; Drug Therapy, Combination; Estradiol; Estrogen Replacement Therap | 1992 |
The effect of sodium fluoride on trabecular architecture.
Topics: Adult; Aged; Bone Density; Female; Fractures, Bone; Humans; Longitudinal Studies; Male; Middle Aged; | 1991 |
The future of fluoride. An update one year after the National Toxicology Program Study.
Topics: Animals; Bone Neoplasms; Female; Fluoridation; Fluorosis, Dental; Fractures, Bone; Humans; Male; Mic | 1991 |
Fluoride and bone--quantity versus quality.
Topics: Calcium; Estrogens; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Sodium Fluoride | 1990 |
The long-term treatment of steroid osteoporosis with fluoride.
Topics: Adult; Aged; Bone Density; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis; Prednis | 1990 |
Fluoride-induced fractures: relation to osteogenic effect.
Topics: Aged; Drug Therapy, Combination; Female; Femoral Neck Fractures; Fractures, Bone; Fractures, Stress; | 1990 |
[What is your diagnosis? Microfractures of the tibia (near the joint) and of the calcaneus caused by fluoride].
Topics: Aged; Calcaneus; Female; Fractures, Bone; Humans; Radiography; Sodium Fluoride; Tibial Fractures | 1990 |
Treatment of osteoporosis with human parathyroid peptide and observations on effect of sodium fluoride.
Topics: Bone Density; Calcium; Drug Therapy, Combination; Estrogen Replacement Therapy; Female; Fractures, B | 1990 |
A newly developed spine deformity index (SDI) to quantitate vertebral crush fractures in patients with osteoporosis.
Topics: Adult; Aged; Anthropometry; Body Height; Calcium; Cholecalciferol; Female; Fractures, Bone; Humans; | 1988 |
The effects of sodium fluoride, calcium phosphate, and vitamin D2 for one to two years on calcium and phosphorus metabolism in postmenopausal women with spinal crush fracture osteoporosis.
Topics: Aged; Bone and Bones; Bone Resorption; Calcium; Calcium Phosphates; Ergocalciferols; Female; Fractur | 1985 |
Sodium fluoride in the treatment of osteoporosis.
Topics: Calcium; Female; Fractures, Bone; Humans; Menopause; Osteoporosis; Sodium Fluoride | 1986 |
[Multidisciplinary study of the prolonged treatment of involution osteoporosis using sodium fluoride with calcium, phosphate and vitamin D].
Topics: Aged; Biopsy; Bone and Bones; Calcium; Drug Therapy, Combination; Female; Fractures, Bone; Humans; M | 1985 |
Osteoporosis.
Topics: Aged; Bone and Bones; Calcium; Estrogens; Female; Forearm Injuries; Fractures, Bone; Hip Fractures; | 1985 |